Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Oxcarbazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.62 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.62 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.84 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.84 |
| ▸ | BLM | P54132 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | P2RX4 | Q99571 | 12/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxcarbazepine SCHEMBL29433241 | 0.92 | KDM4E (1.00) | KDM4EALDH1A1CYP3A4MEN1MAPT | |
| Oxcarbazepine SCHEMBL29359799 | 0.92 | KDM4E (1.00) | KDM4EALDH1A1CYP3A4MEN1MAPT | |
| Oxcarbazepine SCHEMBL35129 | 0.92 | KDM4E (1.00) | KDM4EALDH1A1CYP3A4MEN1MAPT | |
| Oxcarbazepine SCHEMBL4655725 | 0.92 | KDM4E (1.00) | KDM4EALDH1A1CYP3A4MEN1MAPT | |
| Oxcarbazepine SCHEMBL17372732 | 0.90 | KDM4E (0.97) | KDM4EALDH1A1CYP3A4MEN1MAPT | |
| Oxcarbazepine SCHEMBL27944289 | 0.90 | KDM4E (0.97) | KDM4EALDH1A1CYP3A4MEN1MAPT | |
| SCHEMBL18937321 | 0.87 | MAPT (0.63) | KDM4EALDH1A1CYP3A4MEN1MAPT | |
| Oxcarbazepine SCHEMBL2885435 | 0.86 | KDM4E (0.89) | KDM4EALDH1A1CYP3A4MEN1MAPT | |
| Oxcarbazepine SCHEMBL29123953 | 0.86 | ALDH1A1 (0.89) | KDM4EALDH1A1CYP3A4MEN1MAPT | |
| Oxcarbazepine SCHEMBL5652834 | 0.86 | KDM4E (0.89) | KDM4EALDH1A1CYP3A4MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034381-B2 | Process to control particle size | ALPHAPHARM PTY LTD (AU) | 2015-05-19 | — | — | US | claimed |
| CN-1968692-A | Compositions for affecting weight loss | UNIV DUKE (US) | 2007-05-23 | — | — | CN | claimed |
| US-20230390216-A1 | BROMHEXINE FOR THE TREATMENT OF PAIN | KERN KAI UWE (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-3638223-B1 | BROMHEXINE FOR THE TREATMENT OF PAIN | KERN KAI UWE (DE) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023183873-A1 | APTAMERS AND USES THEREOF | MENSURA HEALTH INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-11759439-B2 | Bromhexine for the treatment of pain | KERN KAI UWE (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11053245-B2 | Methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210002280-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20200407362-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200197330-A1 | BROMHEXINE FOR THE TREATMENT OF PAIN | KERN KAI UWE (DE) | 2020-06-25 | — | — | US | disclosed |
| EP-3638223-A1 | BROMHEXINE FOR THE TREATMENT OF PAIN | Kern, Kai-Uwe (DE) | 2020-04-22 | — | — | EP | disclosed |
| EP-2697662-A2 | BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF | Codexis, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2013155504-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| EP-2619202-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | Pfizer Inc (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | PFIZER INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130150391-A1 | Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2590961-A1 | PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS | Pfizer Inc (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012142302-A2 | BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF | CODEXIS, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012038850-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012004698-A1 | PIPERIDINYL PYRIMIDINE AMIDES AS KV7 POTASSIUM CHANNEL OPENERS | PFIZER INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002280-A1 | NOVEL METHODS | HTR2C, HTR3C, DBH | SCN4A 674/4885SCN5A 1270/4885SCN9A 3003/4885 |
| US-20200407362-A1 | NOVEL METHODS | HTR2C, HTR3C, DBH | SCN4A 674/4885SCN5A 1270/4885SCN9A 3003/4885 |
| US-20130150391-A1 | Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers | KCNA7, KCNK17, KCNQ5 | SCN4A 84/4885SCN5A 61/4885SCN9A 138/4885 |
| US-11053245-B2 | Methods | HTR2C, HTR3C, DBH | SCN4A 956/4885SCN5A 1703/4885SCN9A 3629/4885 |
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | KCNQ5, KCNQ1, KCNQ3 | SCN4A 115/4885SCN5A 88/4885SCN9A 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.